- Home
- CHI vs OLMA Comparison
CHI vs OLMA Comparison
Compare CHI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- OLMA
- Stock Information
- Founded
- CHI 2002
- OLMA 2006
- Country
- CHI United States
- OLMA United States
- Employees
- CHI N/A
- OLMA N/A
- Industry
- CHI Investment Managers
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- OLMA Health Care
- Exchange
- CHI Nasdaq
- OLMA Nasdaq
- Market Cap
- CHI 853.5M
- OLMA 725.5M
- IPO Year
- CHI N/A
- OLMA 2020
- Fundamental
- Price
- CHI $11.29
- OLMA $8.78
- Analyst Decision
- CHI
- OLMA Strong Buy
- Analyst Count
- CHI 0
- OLMA 6
- Target Price
- CHI N/A
- OLMA $23.00
- AVG Volume (30 Days)
- CHI 186.2K
- OLMA 1.4M
- Earning Date
- CHI 01-01-0001
- OLMA 11-07-2025
- Dividend Yield
- CHI 9.90%
- OLMA N/A
- EPS Growth
- CHI N/A
- OLMA N/A
- EPS
- CHI N/A
- OLMA N/A
- Revenue
- CHI N/A
- OLMA N/A
- Revenue This Year
- CHI N/A
- OLMA N/A
- Revenue Next Year
- CHI N/A
- OLMA N/A
- P/E Ratio
- CHI N/A
- OLMA N/A
- Revenue Growth
- CHI N/A
- OLMA N/A
- 52 Week Low
- CHI $9.70
- OLMA $2.86
- 52 Week High
- CHI $11.61
- OLMA $13.51
- Technical
- Relative Strength Index (RSI)
- CHI 60.47
- OLMA 48.66
- Support Level
- CHI $10.86
- OLMA $8.44
- Resistance Level
- CHI $11.50
- OLMA $9.05
- Average True Range (ATR)
- CHI 0.16
- OLMA 0.72
- MACD
- CHI 0.01
- OLMA -0.21
- Stochastic Oscillator
- CHI 69.12
- OLMA 48.30
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.